Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4

Conditions

Lymphoma, T-Cell, Peripheral 7Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma 6Leukemia, Myeloid, Acute 6Lymphoma, T-Cell, Cutaneous 5Carcinoma, Non-Small-Cell Lung 5Breast Neoplasms 5Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell 4Lymphoma, Mantle-Cell 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lung Neoplasms 4Hodgkin Disease 4Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 3Urinary Bladder Neoplasms 3Sarcoma 3Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Immunoblastic Lymphadenopathy 3Fallopian Tube Neoplasms 3Burkitt Lymphoma 3Thyroid Neoplasms 2

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22Thiotepa 20Sirolimus 20Azacitidine 20venetoclax 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Hematologic Neoplasms × belinostat × Clear all
NCT02680795 2025-10-20

Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 Genotypes

Acrotech Biopharma Inc.

Phase 1 Completed
17 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT04184869 2023-05-03

Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials

Acrotech Biopharma Inc.

Phase 1 Completed
8 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT02679131 2019-11-20

To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.

Acrotech Biopharma Inc.

Phase 1 Terminated
18 enrolled
Other hematologic neoplasm

Recurrence, Hematologic Neoplasms, Renal Insufficiency

NCT01317927 2015-09-23

A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological Malignancies

Spectrum Pharmaceuticals, Inc

Phase 1 Completed
27 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡